SER-287, AN INVESTIGATIONAL MICROBIOME THERAPEUTIC FOR PATIENTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS, PRODUCES REMISSION ASSOCIATED METABOLITES, REDUCES INTESTINAL EPITHELIAL IL-8 SECRETION AND PROTECTS EPITHELIAL BARRIER FUNCTION IN VITRO

Category Primary study
JournalGastroenterology
Year 2021
This article has no abstract
Epistemonikos ID: 3bfa55b7b95d58cc12a6fe602786bbd640b07245
First added on: Feb 12, 2025